Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
PLoS One ; 9(1): e86977, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24466304

RESUMO

BACKGROUND: It has been well documented that phosphodiesterase-5 inhibitor, sildenafil (SIL) protects against myocardial ischemia/reperfusion (I-R) injury. SIRT1 is part of the class III Sirtuin family of histone deacetylases that deacetylates proteins involved in cellular stress response including those related to I-R injury. OBJECTIVE/HYPOTHESIS: We tested the hypothesis that SIL-induced cardioprotection may be mediated through activation of SIRT1. METHODS: Adult male ICR mice were treated with SIL (0.7 mg/kg, i.p.), Resveratrol (RSV, 5 mg/kg, a putative activator of SIRT1 used as the positive control), or saline (0.2 mL). The hearts were harvested 24 hours later and homogenized for SIRT1 activity analysis. RESULTS: Both SIL- and RSV-treated mice had increased cardiac SIRT1 activity (P<0.001) as compared to the saline-treated controls 24 hours after drug treatment. In isolated ventricular cardiomyocytes, pretreatment with SIL (1 µM) or RSV (1 µM) for one hour in vitro also upregulated SIRT1 activity (P<0.05). We further examined the causative relationship between SIRT1 activation and SIL-induced late cardioprotection. Pretreatment with SIL (or RSV) 24 hours prior to 30 min ischemia and 24 hours of reperfusion significantly reduced infarct size, which was associated with a significant increase in SIRT1 activity (P<0.05). Moreover, sirtinol (a SIRT1 inhibitor, 5 mg/kg, i.p.) given 30 min before I-R blunted the infarct-limiting effect of SIL and RSV (P<0.001). CONCLUSION: Our study shows that activation of SIRT1 following SIL treatment plays an essential role in mediating the SIL-induced cardioprotection against I-R injury. This newly identified SIRT1-activating property of SIL may have enormous therapeutic implications.


Assuntos
Cardiotônicos/metabolismo , Ativação Enzimática/efeitos dos fármacos , Piperazinas/metabolismo , Traumatismo por Reperfusão/prevenção & controle , Sirtuína 1/metabolismo , Sulfonas/metabolismo , Análise de Variância , Animais , Benzamidas/farmacologia , Western Blotting , Cardiotônicos/uso terapêutico , Masculino , Camundongos , Camundongos Endogâmicos ICR , Naftóis/farmacologia , Piperazinas/farmacologia , Piperazinas/uso terapêutico , Purinas/metabolismo , Purinas/farmacologia , Purinas/uso terapêutico , Citrato de Sildenafila , Sirtuína 1/antagonistas & inibidores , Sulfonas/farmacologia , Sulfonas/uso terapêutico
2.
J Bodyw Mov Ther ; 17(3): 356-64, 2013 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-23768282

RESUMO

More than 100 years ago A.T. Still MD founded osteopathic medicine, and specifically described fascia as a covering, with common origins of layers of the fascial system despite diverse names for individual parts. Fascia assists gliding and fluid flow and is highly innervated. Fascia is intimately involved with respiration and with nourishment of all cells of the body, including those of disease and cancer. This paper reviews information presented at the first three International Fascia Research Congresses in 2007, 2009 and 2012 from the perspective of Dr Still, that fascia is vital for organism's growth and support, and it is where disease is sown.


Assuntos
Fáscia/anatomia & histologia , Medicina Osteopática/história , Pesquisa Biomédica , Fáscia/irrigação sanguínea , Fáscia/inervação , História do Século XIX , História do Século XX , Humanos , Osteopatia , Pontos-Gatilho , Estados Unidos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...